Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria

Author： Brown M.C.J.   Nimmerrichter A.A.   Guest J.F.  

Publisher： Elsevier

ISSN： 0924-9338

Source： European Psychiatry, Vol.14, Iss.4, 1999-07, pp. : 230-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK

By Borghi J.   Guest J.F.  

European Psychiatry, Vol. 15, Iss. 6, 2000-09 ,pp. : 378-387

Elsevier

Access to resources Recommend Favorite

A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden

By Löthgren Mickael   Hemels Michiel   François Clément   Jönsson Bengt  

Primary Care Psychiatry, Vol. 9, Iss. 4, 2004-12 ,pp. : 153-162

Informa Healthcare

Access to resources Recommend Favorite

Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression

By Medvedev V.  

Neuroscience and Behavioral Physiology, Vol. 43, Iss. 7, 2013-09 ,pp. : 878-882

Springer Publishing Company

Access to resources Recommend Favorite

Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease

By  

Current Alzheimer Research, Vol. 13, Iss. 7, 2016-07 ,pp. : 809-816

Bentham Science Publishers

Access to resources Recommend Favorite

Bodily symptoms in moderate and severe depression

By Nyboe Jacobsen Lene   Smith Lassen Irene   Friis Preben   Videbech Poul   Wentzer Licht Rasmus  

Nordic Journal of Psychiatry, Vol. 60, Iss. 4, 2006-08 ,pp. : 294-298

Informa Healthcare

Access to resources Recommend Favorite